Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 9/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.34 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.34 |
| ▸ | RORC | P51449 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29991596 | 1.00 | P2RX3 (0.48) | P2RX3KDM4ENPC1RAB9AL3MBTL1 | |
| SCHEMBL15987117 | 1.00 | P2RX3 (0.48) | P2RX3KDM4ENPC1RAB9AL3MBTL1 | |
| SCHEMBL14730353 | 1.00 | P2RX3 (0.48) | P2RX3KDM4ENPC1RAB9AL3MBTL1 | |
| SCHEMBL3704769 | 0.93 | P2RX3 (0.42) | P2RX3KDM4ENPC1RAB9AL3MBTL1 | |
| SCHEMBL16077808 | 0.91 | P2RX3 (0.49) | P2RX3L3MBTL1MCL1BACE1UCHL1 | |
| SCHEMBL13395392 | 0.91 | P2RX3 (0.46) | P2RX3KDM4ENPC1RAB9AL3MBTL1 | |
| SCHEMBL29716162 | 0.91 | P2RX3 (0.46) | P2RX3KDM4ENPC1RAB9AL3MBTL1 | |
| SCHEMBL15984475 | 0.90 | P2RX3 (0.45) | P2RX3L3MBTL1MCL1BACE1UCHL1 | |
| SCHEMBL6864073 | 0.90 | P2RX3 (0.48) | P2RX3MCL1BACE1UCHL1NR1H2 | |
| SCHEMBL16077798 | 0.89 | P2RX3 (0.45) | P2RX3L3MBTL1BACE1UCHL1NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9873707-B2 | Methods and intermediates for preparing macrolactams | MERCK SHARP & DOHME CORP. (US) | 2018-01-23 | — | — | US | disclosed |
| US-20170313745-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD SCIENCES, INC. | 2017-11-02 | — | — | US | disclosed |
| EP-2744336-B1 | PROCESS AND INTERMEDIATES FOR PREPARING MACROLACTAMS | MERCK SHARP & DOHME (US) | 2017-07-05 | — | — | EP | disclosed |
| US-9617310-B2 | Inhibitors of hepatitis C virus | GILEAD SCIENCES, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-9617310-B2 | Inhibitors of hepatitis C virus | GILEAD SCIENCES, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-20160251375-A1 | METHODS AND INTERMEDIATES FOR PREPARING MACROLACTAMS | MERCK SHARP & DOHME CORP. (US) | 2016-09-01 | — | — | US | disclosed |
| US-9242917-B2 | Crystal forms of a HCV protease inhibitor | MERCK SHARP & DOHME LIMITED (GB) | 2016-01-26 | — | — | US | disclosed |
| US-9238604-B2 | Process and intermediates for preparing macrolactams | MERCK SHARP & DOHME CORP. (US) | 2016-01-19 | — | — | US | disclosed |
| US-9073825-B2 | Methods and intermediates for preparing macrolactams | MERCK SHARP & DOHME LIMITED (GB) | 2015-07-07 | — | — | US | disclosed |
| WO-2015095437-A1 | METHODS AND INTERMEDIATES FOR THE PREPARATION OF MACROLACTAMS | MERCK SHARP & DOHME CORP. (US) | 2015-06-25 | — | — | WO | disclosed |
| US-20120121624-A1 | HEPATITIS C VIRUS NS3 PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP (US) | 2012-05-17 | — | — | US | disclosed |
| US-8080654-B2 | Macrocyclic quinoxaline compounds as HCV NS3 protease inhibitors | Insituto di Ricerche di Biologia Molecolare P. Angeletti SpA (IT) | 2011-12-20 | — | — | US | disclosed |
| US-8080654-B2 | Macrocyclic quinoxaline compounds as HCV NS3 protease inhibitors | Insituto di Ricerche di Biologia Molecolare P. Angeletti SpA (IT) | 2011-12-20 | — | — | US | disclosed |
| US-20110224134-A1 | MACROCYCLIC QUINOXALINE COMPOUNDS AS HCV NS3 PROTEASE INHIBITORS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2011-09-15 | — | — | US | disclosed |
| US-20110224134-A1 | MACROCYCLIC QUINOXALINE COMPOUNDS AS HCV NS3 PROTEASE INHIBITORS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2011-09-15 | — | — | US | disclosed |
| US-7973040-B2 | Macrocyclic quinoxaline compounds as HCV NS3 protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2011-07-05 | — | — | US | disclosed |
| US-7973040-B2 | Macrocyclic quinoxaline compounds as HCV NS3 protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2011-07-05 | — | — | US | disclosed |
| WO-2011014487-A1 | HEPATITIS C VIRUS NS3 PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-02-03 | — | — | WO | disclosed |
| US-20100029666-A1 | Macrocyclic Quinoxaline Compounds as HCV NS3 Protease Inhibitors | MERCK SHARP & DOHME LLC | 2010-02-04 | — | — | US | disclosed |
| US-20100029666-A1 | Macrocyclic Quinoxaline Compounds as HCV NS3 Protease Inhibitors | MERCK SHARP & DOHME LLC | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160251375-A1 | METHODS AND INTERMEDIATES FOR PREPARING MACROLACTAMS | EMG1, DPP8, OTUB1 | P2RX3 3918/4885KDM4E 2788/4885NPC1 245/4885 |
| US-20120121624-A1 | HEPATITIS C VIRUS NS3 PROTEASE INHIBITORS | HAVCR2, GTF3C3, CTSC | P2RX3 3494/4885KDM4E 3040/4885NPC1 103/4885 |
| US-20110224134-A1 | MACROCYCLIC QUINOXALINE COMPOUNDS AS HCV NS3 PROTEASE INHIBITORS | KEAP1, CTSC, SPINT2 | P2RX3 2992/4885KDM4E 1621/4885NPC1 532/4885 |
| US-20100029666-A1 | Macrocyclic Quinoxaline Compounds as HCV NS3 Protease Inhibitors | KEAP1, CTSC, SPINT2 | P2RX3 2992/4885KDM4E 1621/4885NPC1 532/4885 |
| US-20170313745-A1 | INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, SLC10A1, LIPC | P2RX3 3658/4885KDM4E 2585/4885NPC1 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.